Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006125 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006125: Completed Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00006125 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006125, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and topotecan in treating patients who have relapsed or refractory intermediate-grade or high-grade non-Hodgkin's lymphoma.
Interventions
- DRUG doxorubicin hydrochloride
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Phase | Phase 2 |
What the finished NCT00006125 record still lists
NCT00006125 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which doxorubicin hydrochloride is the first listed.
NCT00006125 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006125 about?
NCT00006125 is a clinical study titled "Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and topotecan in treating patients who have rel...
What is the current status of trial NCT00006125?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-07.
What interventions are being tested in trial NCT00006125?
The interventions under investigation include: doxorubicin hydrochloride (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00006125?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia